When doctors look for ways to predict how a disease will progress, they often look at the body's internal signals. A new look at data from 1,778 glioma patients shows that a specific marker of inflammation, called the SIRI, can tell a story about the patient's journey.
Patients with a higher SIRI score were found to have significantly worse overall survival and shorter progression-free survival. This means that higher levels of this inflammatory response were linked to a faster progression of the disease.
While these results are clear for the group as a whole, the data is not perfectly uniform. For example, the link between the SIRI score and survival was not significant in the European subgroup of patients. Because of this, experts say more research is needed to find standard ways to use these measurements across different types of people.
